Navigation Links
Phase 1 Study Initiated with Micromet Anti-GM-CS Human Antibody MT203
Date:6/18/2009

BETHESDA, Md., June 18 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced the initiation of the first clinical trial for the anti-granulocyte macrophage colony-stimulating factor (GM-CSF) human antibody MT203 by its collaboration partner Nycomed.

The double-blind, randomized, placebo controlled study will investigate the safety and pharmacokinetics of MT203.

GM-CSF has been shown to play a significant role in various autoimmune and inflammatory diseases, including rheumatoid arthritis, multiple sclerosis, psoriasis, asthma and chronic obstructive pulmonary disease.

Under a 2007 agreement between Micromet and Nycomed, the two companies are jointly developing MT203. Micromet has been primarily responsible for the non-clinical development of MT203, whereas Nycomed will be responsible for the clinical development and commercialization of MT203 going forward.

"The initiation of the first clinical trial represents a major milestone for MT203," comments Christian Itin, President and CEO of Micromet. "Our partner Nycomed is well positioned to pursue the clinical development of MT203 in the field of severe inflammatory and autoimmune diseases."

"We are very pleased with the progress in our collaboration with Micromet," comments Anders Ulman, Executive Vice President Research and Development of Nycomed. "We are looking forward to the results of this first trial as a key milestone in our clinical development program."

About Micromet, Inc.

Micromet, Inc. is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Its pr
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. ORNL finding could help electronics industry enter new phase
2. Transdel Pharmaceuticals Provides Update on Timing of Results for Phase 3 Study
3. FluoroPharma to Present Phase I Study Results of Novel Positron Emission Tomography (PET) Myocardial Perfusion Imaging (MPI) Tracer
4. InteKrin Therapeutics Announces INT131 Phase 2a Results at the 2009 American Diabetes Association Annual Meeting
5. Jazz Pharmaceuticals to Present Data From First Phase III Study of Sodium Oxybate in Patients With Fibromyalgia
6. Medifocus, Inc. receives Authorization Approval from Health Canada to launch its pivotal Phase III clinical study of focused microwave heating for treatment of breast cancer in Canada
7. Results From Phase 1 Clinical Study of PEG-PAL in PKU and Update on Phase 2 Clinical Study
8. Roche to Commence Phase III Trials with Innovative Treatment Designed to Lower Cardiovascular Risk in Diabetes Patients with Recent Heart Attack
9. Pharmasset Initiates Phase 1b Multiple Ascending Dose Clinical Trial of PSI-7851 in Chronic Hepatitis C Patients
10. Sangamo BioSciences Presents Positive Phase 2 ZFP Therapeutic Data at ADA 2009
11. Hyperion Therapeutics Announces Results of Phase I Study in Patients With Liver Cirrhosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... NJ (PRWEB) July 29, 2014 ... the world’s leading healthcare suppliers will utilize the ... 1WorldSync’s product information network to share product information ... and other trading partners across their global supply ... Auto ID at B. Braun: "B. Braun serves ...
(Date:7/29/2014)... July 29, 2014 Mach7 Technologies, ... announced today the release of an enhanced version ... , Mach7’s Physician & Patient Portal enables ... Patients gain access to a comprehensive view of ... seamlessly consolidates complete patient care records and intelligently ...
(Date:7/29/2014)... Collierville, TN (PRWEB) July 29, 2014 ... to the reimbursement model of all hospitals. Studies show ... tsunami.[1] One simple, easy, low cost tool that ... organizational performance by 20 to 25%. , Their secret? ... to one anther at the end of an operational ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 TMG ... Outsourcing solutions for health plans in the Medicare ... Medicaid markets recently held its annual Client Forum ... Under the conference theme, “Partners in Excellence: Navigating ... executives and operations leaders from TMG Health’s Client ...
(Date:7/29/2014)... Kathleen Doheny HealthDay ... Healthy women at low risk of cardiovascular disease may be ... a short time without harming their hearts, according to a ... Initiative, found that hormone replacement therapy had harmful effects on ... they began the hormone treatments, and much further past menopause. ...
Breaking Medicine News(10 mins):Health News:B. Braun Selects 1WorldSync Unique Device Identification and Product Information Solution 2Health News:B. Braun Selects 1WorldSync Unique Device Identification and Product Information Solution 3Health News:Mach7 Technologies’ Physician & Patient Portal Consolidates Patient Care Records across the Enterprise and Simplifies Image Sharing and Communication 2Health News:Mach7 Technologies’ Physician & Patient Portal Consolidates Patient Care Records across the Enterprise and Simplifies Image Sharing and Communication 3Health News:One Brilliant Economic Survival Tool You Can Steal from the World's Best Hospitals 2Health News:One Brilliant Economic Survival Tool You Can Steal from the World's Best Hospitals 3Health News:TMG Health Client Forum Explores Strategies for Success in the Post-Reform Market 2Health News:TMG Health Client Forum Explores Strategies for Success in the Post-Reform Market 3Health News:Early Hormone Therapy May Be Safe for Women's Hearts 2Health News:Early Hormone Therapy May Be Safe for Women's Hearts 3
... This release is available in French . ... enable the region to build research capacity and conduct clinical ... HIV/AIDS and Malaria for the conduct of clinical trials) is ... region to conduct high-quality clinical trials. It will be supported ...
... zeros in on root causes of defects on the ... whose assembly manufacturing quality systems are used by companies ... as they occur, has been named a preferred supplier ... cementing its position in a key growth market for ...
... MUNICH, Feb. 25 Smith & Nephew,s,Orthopaedics ... which,BrainLAB will become the exclusive vendor for developing ... high performance,hip and knee implants. , ... will begin work integrating,the Smith & Nephew portfolio ...
... of Texas M. D. Anderson Cancer Center ... Knife (R) Perfexion(TM), an advanced radiosurgery ... lesions in the head in a single session, ... )"Leksell Gamma Knife Perfexion suits our clinical needs," ...
... Mass. and GAITHERSBURG, Md., Feb. 25 ... a systems biology company focused on identifying ... develop novel therapeutics, molecular diagnostics and patient-specific ... a partnership agreement with Gene Logic, an ...
... Aton Pharma, Inc., a,diversified specialty pharmaceutical company, ... to the TIMOPTIC(R) product line from Merck & ... receptor,blocking agent indicated for the treatment of elevated ... glaucoma. As many as 2.25,million Americans suffer from ...
Cached Medicine News:Health News:CANTAM first African Network of Excellence for clinical trials 2Health News:Sciemetric makes the grade with major medical device manufacturer 2Health News:Smith & Nephew Orthopaedics and BrainLAB Announce Exclusive Computer-Assisted Surgery Development Agreement 2Health News:Smith & Nephew Orthopaedics and BrainLAB Announce Exclusive Computer-Assisted Surgery Development Agreement 3Health News:Smith & Nephew Orthopaedics and BrainLAB Announce Exclusive Computer-Assisted Surgery Development Agreement 4Health News:M. D. Anderson Cancer Center Acquires Leksell Gamma Knife Perfexion for Targeted Brain Lesion Treatments 2Health News:M. D. Anderson Cancer Center Acquires Leksell Gamma Knife Perfexion for Targeted Brain Lesion Treatments 3Health News:Genstruct and Gene Logic Collaborate on Systems Toxicology 2Health News:Genstruct and Gene Logic Collaborate on Systems Toxicology 3Health News:Genstruct and Gene Logic Collaborate on Systems Toxicology 4Health News:Aton Pharma Acquires U.S. TIMOPTIC(R) 2Health News:Aton Pharma Acquires U.S. TIMOPTIC(R) 3
(Date:7/29/2014)... 29, 2014  Drug development for hepatitis C ... rates and the intense need for curative therapy ... is underway as the market moves away from ... easily-tolerated, interferon-free oral therapies. Logo ... mega blockbuster Sovaldi is the first of these ...
(Date:7/29/2014)... WHEAT RIDGE, Colo. , July 29, 2014 ... technology company focused on developing a proprietary electromagnetic ... announced it entered into an agreement under which ... -based Continuation Investments Limited (COT) in an all-stock ... the Company will initially trade on the Australian ...
(Date:7/29/2014)... , July 29, 2014 China Biologic Products, ... leading fully integrated plasma-based biopharmaceutical company in ... to release second quarter 2014 financial results on Tuesday, ... The Company,s management will hold a conference call ... which is 8:00 p.m., Beijing Time on August 6, ...
Breaking Medicine Technology:A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 2A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 3A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 4The BioFusionary Corporation, Inc. Announces Intent To Complete Reverse Takeover Of Australia-Based Continuation Investments Limited 2The BioFusionary Corporation, Inc. Announces Intent To Complete Reverse Takeover Of Australia-Based Continuation Investments Limited 3China Biologic to Report Second Quarter 2014 Financial Results 2China Biologic to Report Second Quarter 2014 Financial Results 3
... 2011 /PRNewswire-iReach/ -- URINOZINC® Plus with Beta-Sitosterol, ... is now available for purchase at select Walmart stores. ... is the only dietary supplement with a US Patent ... Over 2 million bottles have been sold. ...
... CardioMEMS, Inc ., an Atlanta-based medical device company that ... and communication technology for the human body, today announced ... , has been honored with a Ernst & Young ... category for the Alabama/Georgia/Tennessee region.  According to Ernst & ...
Cached Medicine Technology:Walmart Stores Now Offer URINOZINC® Plus With Beta-Sitosterol 2Dr. Jay Yadav, CardioMEMS Founder & CEO, Named Ernst & Young Entrepreneur of the Year® 2Dr. Jay Yadav, CardioMEMS Founder & CEO, Named Ernst & Young Entrepreneur of the Year® 3
... 2 gel holder cassettes, 4 fiber pads, ... buffer chamber, lid with cables, and instructions. ... of Bio-Rad's modular mini electrophoresis system (see ... of mini gels. Its modular electrode assembly ...
... 200 power supply. Flexibility ... Quantitative Transfers. Native Enzyme, ... Faster, Higher-Efficiency Transfers via ... Transfers with Movable Electrodes. ...
... gel holder cassettes, cell with ... pads, blot absorbent paper (15 ... transfer cell, used with the ... efficient, high-intensity electrophoretic transfers. The ...
... for running Criterion precast gels and ... blotter fit for use with the ... the Criterion blotter combines excellent blotting ... Trans-Blot system and the ease-of-use of ...
Medicine Products: